Search This Blog

Tuesday, August 13, 2024

Instil Bio Q2, Update

 

  • In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibody
  • Entered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)